5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up

Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines ahead of patent cliffs and to gain exposure to next-generation therapeutic platforms. Expect increased deal volume and upward pressure on valuations for oncology-focused targets, with strategic capital allocation shifting toward biotech acquisitions and platform investments.

Analysis

Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines ahead of patent cliffs and to gain exposure to next-generation therapeutic platforms. Expect increased deal volume and upward pressure on valuations for oncology-focused targets, with strategic capital allocation shifting toward biotech acquisitions and platform investments.